Alternate molecular genetic pathways in ovarian carcinomas of common histological types

2008 ◽  
Vol 2008 ◽  
pp. 146-148
Author(s):  
A.V. Parwani
2007 ◽  
Vol 38 (4) ◽  
pp. 607-613 ◽  
Author(s):  
Julia Willner ◽  
Kaitlyn Wurz ◽  
Kimberly H. Allison ◽  
Vijaya Galic ◽  
Rochelle L. Garcia ◽  
...  

Database ◽  
2010 ◽  
Vol 2010 (0) ◽  
pp. baq025-baq025 ◽  
Author(s):  
L. L. Baxter ◽  
R. T. Moreland ◽  
A.-D. Nguyen ◽  
T. G. Wolfsberg ◽  
W. J. Pavan

Human Cell ◽  
2014 ◽  
Vol 28 (1) ◽  
pp. 37-43 ◽  
Author(s):  
Kyoko Tanaka ◽  
Mikio Mikami ◽  
Daisuke Aoki ◽  
Kazushige Kiguchi ◽  
Isamu Ishiwata ◽  
...  

2019 ◽  
Vol 6 (2) ◽  
pp. 8-20
Author(s):  
A. B. Villert ◽  
L. A. Kolomiets ◽  
N. V. Yunusova

The severe heterogeneity of ovarian carcinomas on the molecular genetic level is associated with the absence of specific markers of chemoresistance. At the same time, ascites is an attractive biomarker detection fluid because it is easily obtained. The review is dedicated to the latest advances in the study of components characteristics of ascitic fluid in terms of their relationship with chemoresistance. Оwn data are submitted regarding the contents of the IFR system parameters (free IGFs, as well as IGFBP-3, IGFBP-4 and PAPP-A) in ascitic fluids and tumor tissue in disseminated ovarian cancer, which show the importance of their study. It is shown that the proteins level of the IGF system substantially depend on the volume of ascitic fluid. Studying the features of ascitic fluid in ovarian cancer is directly related to the prospect of new opportunities for disseminated ovarian cancer treatment.


2021 ◽  
Vol 11 (11) ◽  
pp. 157-168
Author(s):  
A. Rybin

Highly malignant ovarian cancers are a histopathological diagnosis, but can be multiple diseases at the molecular level. Research aimed at identifying molecular genetic subtypes of ovarian cancer is being conducted to find an answer to the question: can different molecular subgroups influence the choice of treatment? One of the achievements of this direction is the recognition of the dualistic theory of the origin of ovarian carcinomas with their division into High-grade and Low-grade subtypes. However, the data of sequencing of the tumor genome suggest the existence of 6 subtypes of carcinoma, including two LG and four HG subtypes. Patients of subtype C1 are characterized by a high stromal response and have the lowest survival, tumors of C2 and C4 subtypes have a higher rate of intratumoral CD3 + cells, lower stroma gene expression and better survival than C1. The mesenchymal subtype C5 is widely represented by mesenchymal cells, characterized by overexpression of N-cadherins and P-cadherins, low expression of differentiation markers and lower survival than C2 and C4. The use of a consensus algorithm to determine the subtype allows the identification of only a minority of ovarian cancers (approximately 25%). In this regard, the practical significance of this classification still requires additional research, and today it is permissible to talk about the existence of only 2-3 reproducible subtypes. It is thought that it makes sense to randomize tumors into groups with altered expression of angiogenic genes and with overexpression of immune response genes, as in the angiogenic group there is a comparison of the advantage in survival (prescribing bevacizumab improves it, and in the immune group even increases bevacizumab). Molecular subtypes with poorer survival rates (proliferative and mesenchymal) also benefit most from bevacizumab treatment. The review focuses on some advances in understanding molecular, cellular, and genetic changes related to ovarian cancers with the results achieved so far in describing molecular subtypes of ovarian cancer. The available information is the basis for planning further research.


Author(s):  
Javier de la Torre Fernández de Vega ◽  
Jose Luis Sánchez-Iglesias ◽  
Assumpt Perez-Benavente ◽  
Antonio Gil-Moreno ◽  
Rasheda Begum Dina ◽  
...  

Epithelial ovarian cancer presents different histological subtypes, mainly serous, mucinous, endometriod, clear cell, mixed and undifferentiated cell. Molecular genetic studies have led to a new paradigm based on a dualistic model of ovarian carcinogenesis. There is a causal association between endometriosis and specific types of ovarian carcinomas, but the magnitude of the risk is low and endometriosis is not considered a premalignant lesion. Among the endometriosis-associated ovarian tumors adenocarcinoma is the most common (Endometrioid and clear cell) (70%), sarcoma is the second most common malignancy (12%) and rare cell types 6%. The gynecologist should pay special attention to identify patients with endometriosis who may be at an increased risk for ovarian cancer.


BioEssays ◽  
2004 ◽  
Vol 26 (5) ◽  
pp. 479-484 ◽  
Author(s):  
Jennifer M. Cork ◽  
Michael D. Purugganan

2013 ◽  
Vol 2013 ◽  
pp. 1-11 ◽  
Author(s):  
Linda E. Kelemen ◽  
Martin Köbel ◽  
Angela Chan ◽  
Soreh Taghaddos ◽  
Irina Dinu

Epigenomic markers can identify tumor subtypes, but few platforms can accommodate formalin-fixed paraffin-embedded (FFPE) tumor tissue. We tested different amounts of bisulfite-converted (bs) DNA from six FFPE ovarian carcinomas (OC) of serous, endometrioid, and clear cell histologies and two HapMap constitutional genomes to evaluate the performance of the GoldenGate methylation assay. Methylation status at each 1,505 CpG site was expressed asβ-values. Comparing 400 ng versus 250 ng bsDNA, reproducibility of the assay ranged from Spearmanr2=0.41to 0.90, indicating thatβ-values obtained with a lower DNA amount did not always correlate well with the higher amount. Average methylation for the six samples was higher using 250 ng (β-value = 0.45,SD=0.29) than with 400 ng (β-value = 0.36,SD=0.32). Reproducibility between duplicate HapMap samples (r2=0.76to 0.92) was also variable. Using 400 ng input bsDNA,THBS2andERGwere differentially methylated across all histologic types and between endometrioid and clear cell types at <0.1% false discovery rate. Methylation did not always correlate with gene expression (r2=-0.70to 0.15). We found that lower bsDNA overestimates methylation, and, using higher bsDNA amounts, we confirmed a previous report of higher methylation ofTHBS2in clear cell OC, which could provide new insight into biological pathways that distinguish OC histological types.


Sign in / Sign up

Export Citation Format

Share Document